US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.80 against a street estimate of 0.51 — a beat of 56.9%.
Analysts rate Amphastar P a buy (2 buy, 4 hold, 0 sell out of 6) with an average price target of $22.50.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.74% |
| Dimensional Fund Advisors, Inc. | 5.42% |
| State Street Corp | 3.78% |
| Vanguard Capital Management, LLC | 3.63% |
| Fuller & Thaler Asset Management Inc | 3.28% |
| American Century Companies Inc | 2.77% |
| Marshall Wace Asset Management Ltd | 2.41% |
| Geode Capital Management, LLC | 2.30% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 AMPHASTAR PHARMACEUTICALS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $183.9 million (up 5.4% vs Q2 2025: $174.4 million) • Six | 2026-08-06 |
| Results announced · Q3 2026 AMPHASTAR PHARMACEUTICALS Q2 2026 FINANCIAL RESULTS HEADLINE NUMBERS • Net revenues: $183.9 million for Q2 2026, up 5% vs. Q2 2025 ($174.4 million) | 2026-08-06 |
| Board / officer change · Q3 2026 AMPHASTAR PHARMACEUTICALS, INC. — FORM 8-K SUMMARY July 9, 2026 --- OTHER NOTABLE POINTS • Board Expansion: Board of Directors increased authorized | 2026-07-13 |
| Company announcement · Q3 2026 AMPHASTAR PHARMACEUTICALS, INC. - FORM 8-K SUMMARY RISKS & NEGATIVES • FDA Warning Letter Issued: On July 2, 2026, the FDA issued a warning letter t | 2026-07-08 |
| Shareholder vote results · Q2 2026 AMPHASTAR PHARMACEUTICALS, INC. - FORM 8-K SUMMARY June 1, 2026 Annual Stockholder Meeting Results --- OTHER NOTABLE POINTS • Company Details: Dela | 2026-06-03 |
| Quarterly report · Q1 2026 AMPHASTAR PHARMACEUTICALS, INC. – Q1 2026 (MAR 31) SUMMARY HEADLINE NUMBERS • Net Revenue: $171.2 million (Q1 2026) vs. $170.5 million (Q1 2025) – e | 2026-05-07 |
| Proxy statement · Q2 2026 AMPHASTAR PHARMACEUTICALS, INC. – 2026 PROXY STATEMENT SUMMARY --- CEO COMPENSATION & CHANGE • Jack Yongfeng Zhang (CEO) total fiscal 2025 compensa | 2026-04-13 |
| Annual report FY2025 AMPHASTAR PHARMACEUTICALS, INC. – FORM 10-K SUMMARY Fiscal Year Ended December 31, 2025 --- HEADLINE NUMBERS • Net revenues 2025: $719.9 million (d | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Amphastar P — free to start.
Google PlayApp StoreData updated 2026-09-18.